Does the media prefer TENX or AMRN?

In the previous week, Tenax Therapeutics had 5 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Tenax Therapeutics and 2 mentions for Amarin. Tenax Therapeutics' average media sentiment score of 1.05 beat Amarin's score of 0.54 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZNTL or TENX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Tenax Therapeutics N/A -61.54% -57.42%

Does the media refer more to ZNTL or TENX?

In the previous week, Tenax Therapeutics had 4 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Tenax Therapeutics and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.07 beat Tenax Therapeutics' score of 1.05 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TENX or ACB?

Tenax Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 652.69%. Given Tenax Therapeutics' higher probable upside, equities research analysts plainly believe Tenax Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.40 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer TENX or ACB?

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 7 articles in the media. Tenax Therapeutics' average media sentiment score of 1.05 beat Aurora Cannabis' score of 0.49 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, CRDL or TENX?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A

Is CRDL or TENX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Tenax Therapeutics N/A -61.54% -57.42%

Does the media refer more to CRDL or TENX?

In the previous week, Tenax Therapeutics had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for Tenax Therapeutics and 4 mentions for Cardiol Therapeutics. Tenax Therapeutics' average media sentiment score of 1.05 beat Cardiol Therapeutics' score of 0.63 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NMRA or TENX?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A

Is NMRA or TENX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% Tenax Therapeutics N/A -61.54% -57.42%

Tenax Therapeutics (TENX) Competitors

$1.86 -0.09 (-4.62%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.87 +0.01 (+0.54%)

As of 09/11/2026 07:59 PM Eastern

Compare

TENX vs. AMRN, ZNTL, ACB, CRDL, and NMRA

Should you buy Tenax Therapeutics stock or one of its competitors? Tenax Therapeutics's main competitors and comparable companies include Amarin (AMRN), Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), Cardiol Therapeutics (CRDL), and Neumora Therapeutics (NMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tenax Therapeutics compare to Amarin?

Tenax Therapeutics (NASDAQ:TENX) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Tenax Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Amarin has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tenax Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Amarin	-14.56%	-0.20%	-0.14%

Tenax Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 652.69%. Amarin has a consensus target price of $13.00, indicating a potential downside of 5.80%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Tenax Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

In the previous week, Tenax Therapeutics had 5 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Tenax Therapeutics and 2 mentions for Amarin. Tenax Therapeutics' average media sentiment score of 1.05 beat Amarin's score of 0.54 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amarin has higher revenue and earnings than Tenax Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Amarin	$213.65M	1.36	-$38.80M	-$0.99	N/A

Summary

Tenax Therapeutics beats Amarin on 10 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Zentalis Pharmaceuticals currently has a consensus target price of $6.75, indicating a potential upside of 92.31%. Tenax Therapeutics has a consensus target price of $14.00, indicating a potential upside of 652.69%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Tenax Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.73	-$137.06M	-$1.95	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Zentalis Pharmaceuticals has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

In the previous week, Tenax Therapeutics had 4 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Tenax Therapeutics and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.07 beat Tenax Therapeutics' score of 1.05 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics' return on equity of -61.54% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Tenax Therapeutics	N/A	-61.54%	-57.42%

1.7% of Tenax Therapeutics shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Tenax Therapeutics beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to Aurora Cannabis?

Tenax Therapeutics (NASDAQ:TENX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 7 articles in the media. Tenax Therapeutics' average media sentiment score of 1.05 beat Aurora Cannabis' score of 0.49 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenax Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Aurora Cannabis	-32.26%	4.37%	3.45%

Tenax Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Tenax Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Aurora Cannabis	$247.82M	0.98	-$88.13M	-$1.41	N/A

Tenax Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 652.69%. Given Tenax Therapeutics' higher probable upside, equities research analysts plainly believe Tenax Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Tenax Therapeutics beats Aurora Cannabis on 8 of the 14 factors compared between the two stocks.

How does Tenax Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Tenax Therapeutics' return on equity of -61.54% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Cardiol Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Cardiol Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 401.25%. Tenax Therapeutics has a consensus price target of $14.00, indicating a potential upside of 652.69%. Given Tenax Therapeutics' higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Tenax Therapeutics had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for Tenax Therapeutics and 4 mentions for Cardiol Therapeutics. Tenax Therapeutics' average media sentiment score of 1.05 beat Cardiol Therapeutics' score of 0.63 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tenax Therapeutics beats Cardiol Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Tenax Therapeutics compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 531.87%. Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 652.69%. Given Tenax Therapeutics' higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Neumora Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Neumora Therapeutics has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Tenax Therapeutics had 6 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Tenax Therapeutics and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Tenax Therapeutics' score of 1.05 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Very Positive
Tenax Therapeutics	Positive

Tenax Therapeutics' return on equity of -61.54% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Summary

Neumora Therapeutics beats Tenax Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69.61M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	-1.26	799.75	274.94	25.36
Price / Sales	N/A	963.83	686.01	116.83
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	0.18	10.39	10.33	6.20
Net Income	-$52.60M	$2.85B	$3.50B	$358.50M
7 Day Performance	-4.12%	-3.61%	-3.32%	-2.35%
1 Month Performance	1.64%	0.72%	-0.53%	-3.23%
1 Year Performance	-69.56%	3.61%	23.51%	8.79%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	3.7748 of 5 stars	$1.86 -4.6%	$14.00 +652.7%	-69.6%	$69.61M	N/A	N/A	9	Positive News Analyst Forecast Insider Trade Short Interest Increase Gap Up
AMRN Amarin	0.9451 of 5 stars	$14.25 +4.5%	$13.00 -8.8%	-8.1%	$287.91M	$186.23M	N/A	360
ZNTL Zentalis Pharmaceuticals	3.4447 of 5 stars	$4.03 +1.0%	$6.75 +67.5%	+135.6%	$285.97M	N/A	N/A	160
ACB Aurora Cannabis	1.198 of 5 stars	$3.87 -2.0%	N/A	-23.2%	$256.12M	$247.82M	N/A	1,028	Analyst Upgrade
CRDL Cardiol Therapeutics	2.8233 of 5 stars	$2.22 +0.9%	$10.00 +350.5%	+86.4%	$255.59M	N/A	N/A	20	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. AMRN, ZNTL, ACB, CRDL, and NMRA

How does Tenax Therapeutics compare to Amarin?

Summary

How does Tenax Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Tenax Therapeutics compare to Aurora Cannabis?

Summary

How does Tenax Therapeutics compare to Cardiol Therapeutics?

Summary

How does Tenax Therapeutics compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. AMRN, ZNTL, ACB, CRDL, and NMRA

How does Tenax Therapeutics compare to Amarin?

Which has more volatility & risk, TENX or AMRN?

Do insiders and institutionals believe in TENX or AMRN?

Is TENX or AMRN more profitable?

Do analysts rate TENX or AMRN?

Does the media prefer TENX or AMRN?

Which has preferable earnings and valuation, TENX or AMRN?

Summary

How does Tenax Therapeutics compare to Zentalis Pharmaceuticals?

Do analysts recommend ZNTL or TENX?

Which has preferable valuation & earnings, ZNTL or TENX?

Which has more risk & volatility, ZNTL or TENX?

Does the media refer more to ZNTL or TENX?

Is ZNTL or TENX more profitable?

Do insiders & institutionals have more ownership in ZNTL or TENX?

Summary

How does Tenax Therapeutics compare to Aurora Cannabis?

Do insiders and institutionals have more ownership in TENX or ACB?

Does the media prefer TENX or ACB?

Is TENX or ACB more profitable?

Which has more risk and volatility, TENX or ACB?

Which has stronger earnings and valuation, TENX or ACB?

Do analysts rate TENX or ACB?

Summary

How does Tenax Therapeutics compare to Cardiol Therapeutics?

Is CRDL or TENX more profitable?

Which has more volatility & risk, CRDL or TENX?

Which has better earnings & valuation, CRDL or TENX?

Do analysts recommend CRDL or TENX?

Do institutionals and insiders believe in CRDL or TENX?

Does the media refer more to CRDL or TENX?

Summary

How does Tenax Therapeutics compare to Neumora Therapeutics?

Do analysts prefer NMRA or TENX?

Do insiders & institutionals have more ownership in NMRA or TENX?

Which has higher valuation & earnings, NMRA or TENX?

Which has more volatility & risk, NMRA or TENX?

Does the media favor NMRA or TENX?

Is NMRA or TENX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools